Document is current
Any future updates will be listed below
-
Authors
Rettinger, Eva https://orcid.org/0009-0000-2213-2838
Heckl, Dirk
Gibson, Brenda
Sauer, Martin https://orcid.org/0009-0007-2151-8342
Turkiewicz, Dominik https://orcid.org/0009-0001-0386-0714
Kleinschmidt, Katharina
Kalwak, Krzysztof https://orcid.org/0000-0003-1174-5799
Reinhardt, Dirk https://orcid.org/0000-0002-7027-4483
Locatelli, Franco https://orcid.org/0000-0002-7976-3654
Klusmann, Jan-Henning https://orcid.org/0000-0002-1070-0727
,
-
Funding
Funding for this research was provided by:
Frankfurt Cancer Institute, the parents Association “Hilfe für Krebskranke Kinder e.V." C3OMBAT consortium. the Frankfurt Foundation for Children with Cancer
- License Information
-
More Information
Article History
Received: 12 March 2025
Revised: 23 May 2025
Accepted: 27 June 2025
First Online: 9 July 2025
Competing interests
: KK acknowledges research support from Jazz Pharmaceuticals, travel grants from Sobi and Medac, and receives honoraria from Vertex. BG declares honoraria from Vertex. JHK acknowledges advisory roles with Bluebird Bio, Novartis, Roche, and Jazz Pharmaceuticals. FL participated in advisory boards for Amgen, Sanofi, and Vertex; speaker’s bureau for Amgen, Gilead, Miltenyi, Novartis, Sanofi, and SOBI. All other authors declare that the manuscript was written in the absence of any commercial or financial relationships that could be perceived as a potential conflict of interest.
